藥明生物(02269.HK)2019年度淨利潤預增超58%
格隆匯3月4日丨藥明生物(02269.HK)發佈正面盈利預告,集團預期截至2019年12月31日止年度所錄得的歸屬於公司權益股東的利潤相比2018年度歸屬於公司權益股東的利潤增長58%以上。
公告表示,該增長主要是由於憑藉領先的技術平台、行業最佳的項目交付時間及優秀的項目執行過往記錄,集團贏得了更高市場份額,同時集團新增綜合項目數保持快速增長;集團包括雙特異性抗體平台WuXiBody在內的多個擁有自主知識產權的創新技術平台持續受業界青睞;實施集團“跟隨藥物分子發展階段擴大業務”策略帶動收益強勁增長,包括WuXiBody平台產生的里程碑收益及項目成功沿價值鏈上行而產生的里程碑收益;及營運效率提升,部分被新生產基地產能爬坡及隨着集團業務增長而增加的行政開支所抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.